XGEVA (denosumab) is now
available to patients on the PBS for
treatment of bone metastases from
breast cancer or hormone resistant
prostate cancer.
According to research, up to 75
percent of patients with advanced
breast and prostate cancer will
develop bone metastases, a
condition which weakens the bones
and can lead to fractures, spinal cord
compression and severe bone pain.
Clinical trials of the drug
demonstrated a delay in time to
the development of a first
skeletal related event and reduced
the total number of events.
Xgeva is an injection
administered every four weeks,
which targets a protein responsible
for the functioning of cells that
destroy bone in cancer related
bone disease.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 12
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.